101 related articles for article (PubMed ID: 20920870)
61. Influence of promoter region variants of insulin-like growth factor pathway genes on the strength-training response of muscle phenotypes in older adults.
Hand BD; Kostek MC; Ferrell RE; Delmonico MJ; Douglass LW; Roth SM; Hagberg JM; Hurley BF
J Appl Physiol (1985); 2007 Nov; 103(5):1678-87. PubMed ID: 17761791
[TBL] [Abstract][Full Text] [Related]
62. Insulin-like growth factor-I genotype and birthweight.
Twickler TB; de Sain-vander Velden MG; van Doorn J; van Haeften TW
Lancet; 2002 Sep; 360(9337):946. PubMed ID: 12354490
[No Abstract] [Full Text] [Related]
63. Polymorphic CA repeats in the IGF-I gene and breast cancer.
Yu H; Li BD; Smith M; Shi R; Berkel HJ; Kato I
Breast Cancer Res Treat; 2001 Nov; 70(2):117-22. PubMed ID: 11768601
[TBL] [Abstract][Full Text] [Related]
64. Maximal oxygen uptake is associated with allele -202 A of insulin-like growth factor binding protein-3 (IGFBP3) promoter polymorphism and (CA)n tandem repeats of insulin-like growth factor IGF1 in Caucasians from Poland.
Gronek P; Holdys J; Kryściak J; Wieliński D; Słomski R
Acta Biochim Pol; 2014; 61(2):245-52. PubMed ID: 24809065
[TBL] [Abstract][Full Text] [Related]
65. Genetic Polymorphisms in the Somatotropic Axis and Critical Illness: "SNiPping" Away at a "Growing" Canvas!
Srinivasan V
Crit Care Med; 2015 Dec; 43(12):2695-6. PubMed ID: 26575665
[No Abstract] [Full Text] [Related]
66. The estimation of GC repeats in promoter P1 of IGF-1 gene and their influence on IGF-1 plasma levels in stable angina patients.
Burchardt P; Nowak W; Zurawski J; Gozdzicka-Jozefiak A; Siminiak T
Protein J; 2010 Oct; 29(7):524-9. PubMed ID: 20872173
[TBL] [Abstract][Full Text] [Related]
67. Distribution of a single nucleotide polymorphism of insulin-like growth factor-1 in colorectal cancer patients and its association with mucinous adenocarcinoma.
Lin JK; Shen MY; Lin TC; Lan YT; Wang HS; Yang SH; Li AF; Chang SC
Int J Biol Markers; 2010; 25(4):195-9. PubMed ID: 21161940
[TBL] [Abstract][Full Text] [Related]
68. Insulin-like Growth Factor 1 gene polymorphism and breast cancer risk.
Costa-Silva DR; Barros-Oliveira MD; Borges RS; Tavares CB; Borges US; Alves-Ribeiro FA; Silva VC; Silva BB
An Acad Bras Cienc; 2016; 88(4):2349-2356. PubMed ID: 27925035
[TBL] [Abstract][Full Text] [Related]
69. Genotype-phenotype analysis for the polymorphic CA repeat in the insulin-like growth factor-I (IGF-I) gene.
Kato I; Eastham J; Li B; Smith M; Yu H
Eur J Epidemiol; 2003; 18(3):203-9. PubMed ID: 12800944
[TBL] [Abstract][Full Text] [Related]
70. H19 rs217727 genotype and IGF-1/intron -2 dinucleotide CT repeat polymorphism are independently associated with birth weight.
Hewage AS; Jayanthiny P; Tennekoon KH; Kumarasiri JM; De S Wijesundere AP; Karunanayake EH
Endocrine; 2015 Apr; 48(3):1010-2. PubMed ID: 25173192
[No Abstract] [Full Text] [Related]
71. A polymorphic CA repeat in the promoter region of the insulin-like growth factor-I (IGF-I) gene.
Rietveld I; Janssen JA; Van Duijn CM; Lamberts SW
Eur J Epidemiol; 2003; 18(3):191-3. PubMed ID: 12800942
[No Abstract] [Full Text] [Related]
72. A new polymorphism in the cattle IGFBP3 gene.
Thue TD; Buchanan FC
Anim Genet; 2002 Jun; 33(3):242. PubMed ID: 12030939
[No Abstract] [Full Text] [Related]
73. Perplexing polymorphisms: D(i)ps, Sn(i)ps, and trips.
Rosen CJ; Bilezikian JP
J Clin Endocrinol Metab; 1999 Dec; 84(12):4465-6. PubMed ID: 10599703
[No Abstract] [Full Text] [Related]
74. [Noisy silent polymorphisms].
Korzeniewski S; Hofman P; Brest P
Med Sci (Paris); 2013 Feb; 29(2):124-6. PubMed ID: 23452592
[No Abstract] [Full Text] [Related]
75. Influence of the
Gao M; Zhu B; Li P; Zhang G; Chen K; Lv H; Ma R; Zhang L; Fan Y; Kang X
Front Endocrinol (Lausanne); 2018; 9():751. PubMed ID: 30619084
[No Abstract] [Full Text] [Related]
76. Association between acromegaly and a single nucleotide polymorphism (rs2854744) in the IGFBP3 gene.
Gao M; Zhu B; Xu Z; Liu S; Liu J; Zhang G; Gao Y; Fan Y; Kang X
BMC Med Genet; 2018 Oct; 19(1):182. PubMed ID: 30290787
[TBL] [Abstract][Full Text] [Related]
77. Safety of long-term treatment with Pegvisomant: analysis of Spanish patients included in global ACROSTUDY.
Bernabeu I; Pico A; Venegas E; Aller J; Alvarez-Escolá C; García-Arnés JA; Marazuela M; Jonsson P; Mir N; García Vargas M;
Pituitary; 2016 Apr; 19(2):127-37. PubMed ID: 26553421
[TBL] [Abstract][Full Text] [Related]
78. Influence of growth hormone receptor (GHR) exon 3 and -202A/C IGFBP-3 genetic polymorphisms on clinical and biochemical features and therapeutic outcome of patients with acromegaly.
Jallad RS; Trarbach EB; Duarte FH; Jorge AA; Bronstein MD
Pituitary; 2015 Oct; 18(5):666-73. PubMed ID: 25552351
[TBL] [Abstract][Full Text] [Related]
79. Update on prognostic factors in acromegaly: Is a risk score possible?
Fernandez-Rodriguez E; Casanueva FF; Bernabeu I
Pituitary; 2015 Jun; 18(3):431-40. PubMed ID: 24858722
[TBL] [Abstract][Full Text] [Related]
80. Measuring microsatellite conservation in mammalian evolution with a phylogenetic birth-death model.
Sawaya SM; Lennon D; Buschiazzo E; Gemmell N; Minin VN
Genome Biol Evol; 2012; 4(6):636-47. PubMed ID: 22593552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
